首页> 外文期刊>Medical Oncology >Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer
【24h】

Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer

机译:三阴性和非三阴性乳腺癌患者的人口统计学和临床​​病理特征

获取原文
获取原文并翻译 | 示例
           

摘要

We investigate retrospectively the demographic and clinico-pathological characteristics of patients with triple-negative breast cancer (TNBC) compared to those with non-TNBC. Patients with breast cancer diagnosed from 1981 to 2008 in our clinic were retrospectively analyzed. Patient demographics including survival data and tumor characteristics were obtained from charts. A total of 795 patients were assessed in the study, including 140 patients (17.6%) with TNBC and 655 patients (82.4%) with non-TNBC. Patients with non-TNBC were further classified into 3 groups according to hormone receptor (HR) and HER-2 status. Median age was 49 (range 38–60 years) and similar between patients with TNBC and non-TNBC. Patients with TNBC had an increased likelihood of a higher histological grade III compared with HR(+) HER-2(−) subgroup (P 0.001) and lower stage compared with HR(+)/HER2(+) and HR(−)/HER2(+) subgroups (P 0.001 and P = 0.002, respectively). In patients with TNBC, the disease-free survival (DFS) rate was 66% at 5 years. In subgroup analysis of non-TNBCs, 5-year-DFS rates of the patients in HR(+)/HER2(−), HR(+)/HER2(+) and HR(−)/HER2(+) subgroups were 59, 66, and 57%, respectively. There was no significant difference between the TNBC and non-TNBC subgroups (P = 0.238). In multivariate analysis, nodal involvement (RR = 2.8, 95% CI: 0.99–8.3, P = 0.052) and the presence of lymphovascular invasion (RR = 3.2, 95% CI: 1.1–9.2, P = 0.029) were significantly associated with increased recurrence risk in patients with TNBC. Although there are differences in patient and tumor features, patients with TNBC had similar clinical course with those with non-TNBC.
机译:我们回顾性调查与非TNBC相比,三阴性乳腺癌(TNBC)患者的人口统计学和临床​​病理特征。回顾性分析我院1981年至2008年确诊的乳腺癌患者。从图表中获得了包括生存数据和肿瘤特征在内的患者人口统计学信息。该研究共评估了795名患者,包括140例(17.6%)TNBC患者和655例(82.4%)非TNBC患者。根据激素受体(HR)和HER-2的状态,将非TNBC患者进一步分为3组。 TNBC患者和非TNBC患者的中位年龄为49岁(38至60岁)。与HR(+)HER-2(-)亚组相比(P> 0.001),TNBC患者具有更高的组织学III级可能性(P> 0.001),而与HR(+)/ HER2(+)和HR(-)相比则具有较低的分期/ HER2(+)子组(分别为P <0.001和P = 0.002)。 TNBC患者的5年无病生存率(DFS)为66%。在非TNBC的亚组分析中,HR(+)/ HER2(-),HR(+)/ HER2(+)和HR(-)/ HER2(+)亚组患者的5年DFS率为59 ,分别为66%和57%。 TNBC和非TNBC亚组之间无显着差异(P = 0.238)。在多变量分析中,淋巴结受累(RR = 2.8,95%CI:0.99–8.3,P = 0.052)和淋巴管浸润的存在(RR = 3.2,95%CI:1.1–9.2,P = 0.029)与以下因素显着相关: TNBC患者复发风险增加。尽管患者和肿瘤特征存在差异,但TNBC患者的临床病程与非TNBC患者相似。

著录项

  • 来源
    《Medical Oncology》 |2011年第1期|p.75-79|共5页
  • 作者单位

    Department of Medical Oncology, Hacettepe University Institute of Oncology, 06100, Sihhiye Ankara, Turkey;

    Department of Medical Oncology, Hacettepe University Institute of Oncology, 06100, Sihhiye Ankara, Turkey;

    Department of Medical Oncology, Hacettepe University Institute of Oncology, 06100, Sihhiye Ankara, Turkey;

    Department of Medical Oncology, Hacettepe University Institute of Oncology, 06100, Sihhiye Ankara, Turkey;

    Department of Medical Oncology, Hacettepe University Institute of Oncology, 06100, Sihhiye Ankara, Turkey;

    Department of Medical Oncology, Hacettepe University Institute of Oncology, 06100, Sihhiye Ankara, Turkey;

    Department of Medical Oncology, Hacettepe University Institute of Oncology, 06100, Sihhiye Ankara, Turkey;

    Department of Medical Oncology, Hacettepe University Institute of Oncology, 06100, Sihhiye Ankara, Turkey;

    Department of Medical Oncology, Hacettepe Univer;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Triple negative; Breast cancer; Non-triple negative; Prognosis;

    机译:三重阴性;乳腺癌;非三联阴性;预后;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号